# Pancreatic and Biliary Pathology

## Overview

Pancreatic and biliary pathology spans a spectrum from precursor lesions to aggressive malignancies. Pancreatic ductal adenocarcinoma remains one of the deadliest cancers, while pancreatic neuroendocrine tumors and cystic neoplasms have markedly different biologies. The pathologist must be adept at recognizing precursor lesions and handling limited cytologic and biopsy material.

## Pancreatic Ductal Adenocarcinoma (PDAC)

### Epidemiology and Risk Factors

Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer death, with a 5-year survival of approximately 12 percent. Risk factors include smoking, chronic pancreatitis, obesity, diabetes, and family history. Hereditary syndromes that predispose to PDAC include BRCA1/2, PALB2, ATM, Lynch syndrome, Peutz-Jeghers syndrome, and familial pancreatitis (PRSS1 mutations).

### Molecular Pathogenesis

KRAS mutation (at codon 12) is the earliest and most common molecular event, present in over 90 percent of PDAC. CDKN2A (p16) inactivation occurs in approximately 95 percent, TP53 mutation in approximately 75 percent, and SMAD4 (DPC4) loss in approximately 55 percent of cases. SMAD4 loss is associated with widespread metastatic disease. The progression model follows a stepwise sequence from normal epithelium through PanIN-1 (low-grade), PanIN-2, PanIN-3 (high-grade) to invasive carcinoma.

### Histology

The hallmark is infiltrating glands embedded in desmoplastic stroma, and the key diagnostic challenge is distinguishing malignant glands from reactive or chronic pancreatitis changes. Well-differentiated tumors show variably sized glands with mucin-containing columnar epithelium, and nuclear atypia may be deceptively mild. Diagnostic features include incomplete lumina, haphazard gland arrangement, perineural invasion, and vascular invasion. Perineural invasion is present in over 80 percent of cases and represents a hallmark feature. Poorly differentiated tumors grow in solid sheets, single cells, or sarcomatoid patterns.

### Distinguishing PDAC from Chronic Pancreatitis

Several features favor PDAC over chronic pancreatitis: irregular gland size and shape (versus evenly spaced lobular architecture in pancreatitis), incomplete glandular lumina with intraluminal necrotic debris, haphazard arrangement with glands adjacent to muscular vessels or nerves, and perineural invasion (rare in reactive conditions). SMAD4 immunohistochemistry shows loss of nuclear staining in approximately 55 percent of PDAC while being retained in reactive conditions. Aberrant p53 staining (overexpression or null pattern) also supports carcinoma.

### Reporting and Staging

Synoptic reporting should include tumor size, site, margin status (pancreatic neck, uncinate, bile duct, duodenal, and retroperitoneal margins), and lymph node status. Color-coded inking is recommended for Whipple specimens. The R0 versus R1 distinction uses a 1 mm margin clearance threshold in many protocols.

## Pancreatic Precursor Lesions

### Pancreatic Intraepithelial Neoplasia (PanIN)

PanINs are microscopic lesions (less than 5 mm) within small pancreatic ducts. Low-grade PanIN (formerly PanIN-1 and PanIN-2) shows mucinous columnar epithelium with mild atypia. High-grade PanIN (formerly PanIN-3) shows severe atypia, mitoses, and cribriform or papillary architecture, equivalent to carcinoma in situ. These are incidental findings without macroscopic correlates and are not clinically manageable.

### Intraductal Papillary Mucinous Neoplasm (IPMN)

IPMNs are macroscopic (1 cm or larger) mucin-producing neoplasms within the pancreatic duct system. Main duct IPMN involves the main pancreatic duct (5 mm or greater dilation) and carries a higher malignancy risk (40 to 70 percent). Branch duct IPMN produces cystic dilation of side branches with a lower malignancy risk (15 to 25 percent). Mixed type involves both.

#### Subtypes by Epithelial Type

The gastric type features foveolar epithelium, is most common in branch duct IPMN, and typically shows the lowest dysplasia grade. The intestinal type has villous or papillary architecture (MUC2-positive, CDX2-positive) and when invasive usually produces colloid (mucinous) carcinoma. The pancreatobiliary type shows complex papillae (MUC1-positive) and when invasive usually produces tubular adenocarcinoma with worse prognosis. The oncocytic type, featuring arborizing papillae with oncocytic cells, has been reclassified as intraductal oncocytic papillary neoplasm (IOPN).

#### Dysplasia Grading

The WHO 5th edition uses a simplified two-tier system: low-grade (mild to moderate atypia with maintained architecture) and high-grade (severe atypia, cribriform or solid growth, mitoses, loss of polarity).

### Mucinous Cystic Neoplasm (MCN)

MCNs occur almost exclusively in women and arise in the body or tail of the pancreas. They are macrocystic lesions with no communication with the ductal system. The defining feature is ovarian-type stroma (positive for estrogen receptor, progesterone receptor, and inhibin) beneath neoplastic mucinous epithelium. They are graded as low-grade versus high-grade dysplasia. When completely excised without invasion, the prognosis is excellent.

## Pancreatic Neuroendocrine Tumors (PanNET)

### Classification and Grading (WHO 2022)

Well-differentiated PanNETs are graded as G1 (mitotic rate less than 2 per 10 HPF, Ki-67 less than 3 percent), G2 (mitotic rate 2 to 20 per 10 HPF, Ki-67 3 to 20 percent), or G3 (mitotic rate greater than 20 per 10 HPF, Ki-67 greater than 20 percent, but still well-differentiated). Poorly differentiated pancreatic neuroendocrine carcinoma (PanNEC) shows either small cell or large cell morphology, harbors TP53 and RB1 mutations rather than MEN1/DAXX/ATRX, and carries an aggressive biology with poor prognosis.

| Category | Differentiation | Mitotic Rate (/10 HPF) | Ki-67 Index | Key Mutations |
|---|---|---|---|---|
| PanNET G1 | Well-differentiated | <2 | <3% | MEN1, DAXX/ATRX |
| PanNET G2 | Well-differentiated | 2–20 | 3–20% | MEN1, DAXX/ATRX |
| PanNET G3 | Well-differentiated | >20 | >20% | MEN1, DAXX/ATRX |
| PanNEC | Poorly differentiated | >20 | >20% (often >50%) | TP53, RB1 |

### Histology

Well-differentiated PanNETs have uniform round cells with salt-and-pepper chromatin arranged in nested, trabecular, or gyriform architecture. They are positive for synaptophysin and chromogranin A. Ki-67 is essential for grading. Loss of DAXX or ATRX by IHC is associated with alternative lengthening of telomeres (ALT) and has prognostic significance.

### Functional Tumors

Insulinoma is the most common functional PanNET, causing hypoglycemia, and is usually small and benign. Gastrinoma produces Zollinger-Ellison syndrome with peptic ulcer disease and may be duodenal or pancreatic, often located in the gastrinoma triangle. Glucagonoma, VIPoma, and somatostatinoma are rare entities with characteristic clinical syndromes. Non-functional PanNETs are the most common overall and present with mass effect.

## Biliary Pathology

### Cholangiocarcinoma

Intrahepatic cholangiocarcinoma presents as a mass-forming lesion with sclerotic stroma and infiltrating glands (CK7-positive, CK19-positive). Perihilar cholangiocarcinoma (Klatskin tumor) involves the hepatic duct bifurcation and may be periductal infiltrating or mass-forming. Distal cholangiocarcinoma involves the common bile duct and histologically resembles PDAC. Risk factors include PSC, liver flukes (Opisthorchis, Clonorchis), hepatolithiasis, and Caroli disease.

### Ampullary Carcinoma

Ampullary carcinoma is classified as intestinal type or pancreatobiliary type, with significantly different prognoses. The intestinal type resembles colorectal adenocarcinoma (CDX2-positive, CK20-positive, MUC2-positive) and carries a better prognosis. The pancreatobiliary type is CK7-positive and MUC1-positive with worse prognosis similar to PDAC. Overall, ampullary tumors have better prognosis than PDAC at the same stage.

### Gallbladder Carcinoma

Gallbladder carcinoma is strongly associated with gallstones, porcelain gallbladder, and anomalous pancreaticobiliary duct junction. Most are adenocarcinomas, often discovered incidentally in cholecystectomy specimens. The distinction between T1a (lamina propria invasion) and T1b (muscular layer invasion) is critical: T1b and above generally require re-resection with hepatectomy and lymphadenectomy. All cholecystectomy specimens must be opened and examined, with any mural thickening or mucosal irregularity sampled histologically.

<image>A medical illustration of pancreatic ductal adenocarcinoma. Panel A: Low-power view showing irregular infiltrating glands in a dense desmoplastic stroma adjacent to a large nerve bundle, contrasted with a trapped benign pancreatic duct showing uniform round architecture. Panel B: High-power view showing an angulated malignant gland with nuclear pleomorphism, incomplete lumen formation, and intraluminal necrotic debris. Panel C: Perineural invasion with tumor glands wrapping circumferentially around a nerve fascicle. Panel D: SMAD4 immunostain showing complete loss of nuclear staining in carcinoma cells (negative) with retained expression in surrounding stromal cells (positive internal control).</image>

<image>A medical illustration of pancreatic cystic neoplasms. Panel A (Main duct IPMN, intestinal type): Dilated main pancreatic duct lined by villous papillary epithelium with goblet cells, MUC2 positivity shown in inset. Panel B (Branch duct IPMN, gastric type): Cystically dilated branch duct lined by bland foveolar-type mucinous epithelium with minimal atypia. Panel C (Mucinous cystic neoplasm): Mucinous epithelial lining overlying ovarian-type stroma with spindle cells, ER immunostain inset showing nuclear positivity in the stroma. Panel D (PanIN progression): Three small ducts showing the spectrum from low-grade PanIN (flat mucinous epithelium with mild atypia) to high-grade PanIN (papillary architecture with severe cytologic atypia, loss of polarity, and mitotic figures).</image>

<image>A medical illustration of pancreatic neuroendocrine tumors. Panel A: Low-power view showing a well-circumscribed tumor with nested and trabecular architecture. Panel B: High-power view showing uniform round cells with salt-and-pepper chromatin and moderate eosinophilic cytoplasm. Panel C: Ki-67 immunostain showing a low proliferative index (<3%, G1) with scattered positive nuclei. Panel D: Contrast with poorly differentiated pancreatic neuroendocrine carcinoma showing sheet-like growth, high mitotic rate, geographic necrosis, and Ki-67 inset showing >50% labeling index.</image>

## Clinical Pearls

The most reliable way to distinguish well-differentiated PDAC from chronic pancreatitis on biopsy is to look for perineural invasion, incomplete glandular lumina, and haphazard gland distribution adjacent to muscular vessels. SMAD4 loss by immunohistochemistry, when present, is essentially diagnostic of carcinoma. In IPMN, the epithelial subtype predicts the type of invasive carcinoma: intestinal-type IPMN gives rise to colloid (mucinous) carcinoma with better prognosis, while pancreatobiliary-type IPMN gives rise to tubular adenocarcinoma with worse prognosis similar to conventional PDAC.

Ki-67 is the single most important ancillary test for PanNET grading; it should always be counted in the hotspot area with both the mitotic rate and Ki-67 index reported. Distinguishing well-differentiated PanNET G3 from poorly differentiated PanNEC is critical because treatment differs substantially: sunitinib or everolimus for PanNET G3 versus platinum-based chemotherapy for PanNEC. DAXX/ATRX loss favors PanNET while TP53/RB1 abnormalities characterize PanNEC. All incidental gallbladder lesions require careful pathologic evaluation, as T1b gallbladder carcinoma (muscular layer invasion) warrants re-resection, while T1a (lamina propria only) can be managed with cholecystectomy alone.

## References
- WHO Classification of Tumours Editorial Board. *WHO Classification of Tumours: Digestive System Tumours*. 5th ed. IARC; 2019.
- Hruban RH, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. *Am J Surg Pathol*. 2004;28(8):977-987.
- Tanaka M, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. *Pancreatology*. 2017;17(5):738-753.
- Amin MB, et al. *AJCC Cancer Staging Manual*. 8th ed. Springer; 2017.
- Basturk O, et al. A revised classification system and recommendations from the Baltimore Consensus Meeting for neoplastic precursor lesions in the pancreas. *Am J Surg Pathol*. 2015;39(12):1730-1741.